Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Multiple-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double-Blind, Multiple-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rezafungin (Primary)
  • Indications Aspergillosis; Candidaemia; Candidiasis
  • Focus Adverse reactions
  • Sponsors Cidara Therapeutics

    • Most Recent Events

    • 16 Aug 2021 Results of a PopPK model analysis characterizing disposition of rezafungin in plasma following IV administration using data from three clinical studies: NCT02516904, NCT02551549 and NCT02734862 published in the Antimicrobial Agents and Chemotherapy
    • 19 Mar 2018 Results assessing population pharmacokinetic analyses for rezafungin efficacy using pooled data from two phase 1 studies, were published in the Antimicrobial Agents and Chemotherapy.
    • 06 Dec 2016 Results of PK-pharmacodynamic data analysis from two phase I dose-escalation studies (NCT02516904 and NCT02551549), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top